摘要
目的探讨表皮生长因子受体一酪氨酸激酶抑制剂(EGFR—TKI)治疗晚期非小细胞肺癌(NSCLC)以及肺癌合并脑转移患者的疗效、预后及不良反应。方法回顾性分析2007年1月至2012年8月福建省立医院收治的接受EGFR—TKI治疗的晚期NSCI。C患者临床资料,所有患者口服EGFR—TKI直到病变进展或出现不可耐受的不良反应。结果52例晚期NSCI。C患者接受EGFR—TKI治疗的客观缓解率(ORR)为34.6%(18/52),疾病控制率(DCR)为75.0%(39/52),中位无进展生存期(PFS)为6.O个月,中位总生存期(MST)为18.O个月。腺癌、不吸烟、服药前肿瘤大小〈5cm的患者DCR高于非腺癌、吸烟、服药前肿瘤大小≥5cm者(P〈O.05)。生存分析示服药前肿瘤大小〈5cm、疾病控制者的中位PFS优于服药前肿瘤大小≥5cm、疾病进展者(P〈0.05)。而无吸烟史、服药前肿瘤大小〈5cm者的MST优于有吸烟史、服药前肿瘤大小≥5cm者(P〈0.05)。21例肺癌合并脑转移患者口服EGFR-TKI治疗后颅内病灶的ORR为38.1%,DCR为90.5%;全身病变的ORR为38.1%,DCR为85.7%。本研究中最常见的不良反应为皮疹(25.0%)、皮肤瘙痒(19.2%)。结论EGFR—TKI治疗晚期NSCI。C是有效、安全的;EGFR—TKI对脑转移存在一定疗效。
Objective To explore the efficacy, prognosis, and side effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for advanced non-small cell lung cancer and lung cancer with brain metastasis, Methods Clinical datas of advanced non-small cell lung cancer who received EGFR-TKI treatment in Fujian Provincial Hospital from January 2007 to August 2012 were retrospectively analyzed. All patients received EGFR-TKI until the disease progression or intolerable toxicity. Results The objective response rate (ORR) and the disease control rate (DCR) after administration of EGFR-TKI were 34.6% ( 18/52 ) and 75.0% ( 39/52 ), respectively. The median progression free survival time and overall survival time were six months and 18 months, respectively. The DCR in patients with adenocarcinoma, non-smoking, and tumor size ≥ 5 cm was higher than that in patients with non-adenocarcinoma, smokers and tumor size ≥ 5 cm (P 〈 0.05). Survival analysis suggested that the median progression survival in patients with tumor size %5 em and stable disease was longer than that in patients with tumor size ≥5 cm and progression disease ( P〈 0.05). The median survival time in non-smokers and patients of tumor size ≥ 5 cm was longer than that in smokers and patients of tumor size ≥5 cm ( P〈0.05). Among 21 cases of lung cancer with brain metastasis treated with EGFR-TKI,overall ORR and DCR of intracranial lesions were 38.1% and 90.5 %, respectively. The ORR and DCR of systemic disease were 38.1% and 85.7 %, respectively. The most common side effectswere rash (25.0%) and pruitus (19.2%). Conclusions of advanced non-small cell lung cancer patients. EGFR cancer patients. EGFR-TKI is effective and safe in the treatment FKI may be effective on brain metastases in brag
出处
《国际呼吸杂志》
2013年第24期1841-1847,共7页
International Journal of Respiration
基金
福建省自然科学基金项目(2011J01130)
关键词
表皮生长因子受体-酪氨酸激酶抑制剂
非小细胞肺癌
疗效
预后
Epidermal growth factor receptor-tyrosine kinase inhibitor
Non-small cell lungcancer
Efficacy
Prognosis